We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

16 hedge funds and large institutions have $18M invested in Ambrx Biopharma Inc in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

14% more funds holding

Funds holding: 14 → 16 (+2)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

60% less capital invested

Capital invested by funds: $45.4M → $18M (-$27.4M)

Holders
16
Holders Change
+2
Holders Change %
+14.29%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$109K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$87.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$39.6K
4
Citadel Advisors
Citadel Advisors
Florida
+$25K
5
Millennium Management
Millennium Management
New York
+$22.5K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$554K
2
OCA
Octagon Capital Advisors
New York
-$325K
3
CAM
Cormorant Asset Management
Massachusetts
-$309K
4
Norges Bank
Norges Bank
Norway
-$165K
5
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$5.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$3.88M -$554K -269,212 -7%
BlackRock
2
BlackRock
New York
$3.08M -$109 -53 -0%
CAM
3
Cormorant Asset Management
Massachusetts
$2.52M -$309K -149,997 -6%
AG
4
Artal Group
Luxembourg
$2.32M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$2.19M – – –
FI
6
Fosun International
China
$2.09M – – –
SCM
7
Suvretta Capital Management
New York
$1.61M – – –
Millennium Management
8
Millennium Management
New York
$123K +$22.5K +10,916 +11%
Renaissance Technologies
9
Renaissance Technologies
New York
$69K +$109K +53,000 +482%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$46K +$87.4K +42,453 New
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$21K +$39.6K +19,220 New
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$18K -$5.66K -2,748 -14%
Citadel Advisors
13
Citadel Advisors
Florida
$13K +$25K +12,116 New
UBS Group
14
UBS Group
Switzerland
$9K +$15.9K +7,725 +3,192%
OCA
15
Octagon Capital Advisors
New York
– -$325K -122,800 Closed
Norges Bank
16
Norges Bank
Norway
– -$165K -62,396 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– +$86 +42 New

AMAM Hedge Fund Activity: Q3 2022 in Review

16 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q3 2022, worth a combined $18M — down 60% from $45.4M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new AMAM positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $109K. The largest seller was Fidelity Investments, cutting an estimated $554K.

  • 16 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q3 2022, up from 14 in Q2 2022.
  • Funds reported $18M of Ambrx Biopharma Inc stock for Q3 2022, down 60% quarter-over-quarter.
  • 4 funds opened new Ambrx Biopharma Inc positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest Ambrx Biopharma Inc buyer in Q3 2022 was Renaissance Technologies, an estimated $109K added.
  • The largest Ambrx Biopharma Inc seller in Q3 2022 was Fidelity Investments, an estimated $554K sold.

Based on aggregated 13F filings for Q3 2022.